Collateral for a security interest recorded Apr 24, 2013 (Goldman Sachs Lending Partners LLC).
Term ends no later than Dec 11, 2029 · Low confidence
20-year base term ends Dec 11, 2029
In force on USPTO's status record and by its fee record. A terminal disclaimer on file may shorten this term, possibly to a date already past; its reference document is unresolved, so the date above is an upper bound and no earlier date is guessed.
Filed Jul 8, 2011 as application 13/179,315 · Granted Jul 17, 2012
Base term, 20 years from filing
Today
2009
2029
Clock starts
Dec 11, 2009
Dec 11, 2009
Ends no later than
Dec 11, 2029
Dec 11, 2029
Granted
Jul 17, 2012
Jul 17, 2012
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
Unresolved
Terminal disclaimer
On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
13
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. All three maintenance fees are recorded paid; no more fees are due. Confidence: Low. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Dec 11, 2009, when application 12/636,613, the earliest non-provisional in its chain, was filed (this one was filed Jul 8, 2011); a parent in its chain could not be resolved (the next row) | Dec 11, 2029 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | no later than Dec 11, 2029 | Low confidence |
This family
| Application 12/636,613 | Abandoned not computed | not computed |
| Application 13/179,402 | Abandoned not computed | not computed |
| Application 13/179,363 | Abandoned not computed | not computed |
| Application 13/179,336 | Abandoned not computed | not computed |
| US 8,222,270 | this patent no later than Dec 2029 | no later than Dec 2029 |
| Application 13/181,507 | Abandoned not computed | not computed |
| US 8,236,816 | In force no later than Dec 2029 | no later than Dec 2029 |
| US 8,299,109 | In force no later than Dec 2029 | no later than Dec 2029 |
8 of 13 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
The 40 most recent of 69 recorded documents are shown; the 29 earliest are not. Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Bausch Health, Canada Inc. / Sante Bausch, Canada Inc. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | ICN Polfa Rzeszow Spolka Akcyjna (A/K/A ICN Polfa Rzeszow S.A.) | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Orapharma, Inc. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Przedsiebiorstwo Farmaceutyczne Jelfa Spolka Akcyjna (A/K/A Przedsiebiorstwo Farmaceutyczne Jelfa S.A.) | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | Solta Medical Dutch Holdings B.V. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | V-Bac Holding Corp. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | VRX Holdco LLC | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | 1261229 B.C. Ltd. | Release of Security Interest |
| Apr 8, 2025 reel/frame not recorded | Barclays Bank PLC, as Collateral Agent | 1530065 B.C. Ltd. | Release of Security Interest |
| Jun 13, 2025 Reel 71564, frame 463 | Medicis Pharmaceutical Corporation; Orapharma, Inc.; Bausch Health US, LLC (F/K/A Valeant Pharmaceuticals North America LLC); Precision Dermatology, Inc.; Salix Pharmaceuticals, Inc.; Santarus, Inc.; Bausch Health Americas, Inc.; Solta Medical, Inc. | The Bank of New York Mellon | U.S. Patent Security Agreement |
| Jun 13, 2025 Reel 71566, frame 200 | Medicis Pharmaceutical Corporation; Orapharma, Inc.; Bausch Health US, LLC (F/K/A Valeant Pharmaceuticals North America LLC); Precision Dermatology, Inc.; Salix Pharmaceuticals, Inc.; Santarus, Inc.; Bausch Health Americas, Inc.; Solta Medical, Inc. | Jpmorgan Chase Bank, N.a. | U.S. Patent Security Agreement |
| Nov 20, 2025 Reel 73637, frame 1 | The Bank of New York Mellon, as Notes Collateral Agent | Aton Pharma, Inc.; Bausch & Lomb Incorporated; Bausch & Lomb Pharma Holdings Corp.; Commonwealth Laboratories, LLC; Dow Pharmaceutical Sciences, Inc.; Ecr Pharmaceuticals Co., Inc.; Laboratoire Chauvin S.A.S.; Medicis Pharmaceutical Corporation; Onpharma Inc.; Orapharma, Inc.; Precision Dermatology, Inc.; Salix Pharmaceuticals, Ltd.; Salix Pharmaceuticals, Inc.; Santarus, Inc.; Solta Medical, Inc.; Synergetics USA, Inc.; Technolas Perfect Vision GmbH; Valeant Canada LP; Valeant Pharmaceuticals International; Valeant Pharmaceuticals International, Inc.; Valeant Pharmaceuticals North America LLC; Wirra IP Pty Limited; Valeant Pharma Poland SP. Z O.O.; Valeant Pharmaceuticals Luxembourg S.A R.L.; Valeant Pharmaceuticals Ireland Limited | Release of Security Interest |
| Nov 20, 2025 Reel 73654, frame 242 | The Bank of New York Mellon, as Notes Collateral Agent | Bausch & Lomb Incorporated; Bausch Health US, LLC; Solta Medical, Inc.; Medicis Pharmaceutical Corporation; Salix Pharmaceuticals, Inc.; Salix Pharmaceuticals, Ltd.; Santarus, Inc.; Orapharma, Inc.; Precision Dermatology, Inc.; Bausch Health Americas, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Aton Pharma, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch & Lomb Incorporated | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch & Lomb Pharma Holdings Corp. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Commonwealth Laboratories, LLC | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Dow Pharmaceutical Sciences, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Ecr Pharmaceuticals Co., Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Laboratoire Chauvin S.A.S. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Medicis Pharmaceutical Corporation | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Onpharma Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Orapharma, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Precision Dermatology, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Salix Pharmaceuticals, Ltd. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Salix Pharmaceuticals, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Santarus, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Solta Medical, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Synergetics USA, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Technolas Perfect Vision GmbH | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Canada LP | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Pharmaceuticals International | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Pharmaceuticals International, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Pharmaceuticals North America LLC | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Wirra IP Pty Limited | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Pharma Poland SP. Z O.O. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Pharmaceuticals Luxembourg S.A R.L. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Pharmaceuticals Ireland Limited | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch Health Americas, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch Health US, LLC | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Dec 2029
Term ends no later than Dec 11, 2029. No further fees fall due before then
Note
A terminal disclaimer is on file and its reference is not resolved. No cap is applied and none is guessed
Open question
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than Dec 11, 2029. We will not guess the cap.
Citations
24
later US patents cite this one
That is top 25% of utility patents granted in 2012 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
This computed term ends no later than the date shown; an unresolved terminal disclaimer may end it earlier. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.